{"name":"Aspen Pharmacare","slug":"aspen-pharma","ticker":"APN.JO","exchange":"JSE (Johannesburg)","domain":"aspenpharma.com","description":"Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange (JSE) in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals (ARVs) and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through \"fill and finish\", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union.","hq":"Durban, South Africa","founded":0,"employees":"9128","ceo":"Stephen Saad","sector":"Specialty / Sterile Injectables / Branded Generics","stockPrice":14092,"stockChange":-104,"stockChangePercent":-0.73,"marketCap":"$3.8B","metrics":{"revenue":2585062233.644507,"revenueGrowth":-4.3,"grossMargin":43,"rdSpend":0,"netIncome":-109612654.242,"cash":341098055.8024366,"dividendYield":1.49,"peRatio":11.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Mebex patent cliff ($10.8M at risk)","drug":"Mebex","type":"patent_expiry","sentiment":"negative"},{"date":"2026-06-01","label":"Pentacarinat patent cliff ($8.1M at risk)","drug":"Pentacarinat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Aspen Pharmacare reports strong earnings for FY2024","summary":"Aspen Pharmacare reported strong earnings for FY2024, driven by growth in its sterile injectables and branded generics business.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Aspen Pharmacare acquires generic injectables business from Sandoz","summary":"Aspen Pharmacare has acquired the generic injectables business from Sandoz, expanding its portfolio of sterile injectables.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOQmVsVGViaDJsbFhGTDVLbUN0NjNmeFcxbEZ1QnI4R003cEplZlJhdHF0WEh0amJSbERZdzBObHhZdjdhVGVzd0wyR3laa2Y1VmJKaEpJN1NkLUtZVDM4Mm8tczBXZWY5T3hNWUJDajlLRE1lVjVtOVYxdERPV2N3ZDd3eThERHRqNDRLUnlpbTBlNWJRUnVQeWJuQy1zMnlkX0l5Qw?oc=5","date":"2026-04-03","type":"pipeline","source":"Yahoo Finance","summary":"Aspen Pharmacare Holdings Insider Ups Holding During Year - Yahoo Finance","headline":"Aspen Pharmacare Holdings Insider Ups Holding During Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE5ncndiai1uNjg0RW5YbC1pT3ZnbUFWZ3BWYUw3eUM2QmpJNlhmTldvYnlmRG9RODhvc0cyQ0F5Sm1hamZWOWNDS3FRN2NOTkJKQUZYaFptWnI0LVFKT21uODhnOXl4ajN5dEZTZkEzMA?oc=5","date":"2026-03-30","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Cereno Scientific AB (publ) (CRNO-B.ST) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore","headline":"Cereno Scientific AB (publ) (CRNO-B.ST) Analyst insights, Price targets and Recommendations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNc1FhQTJvaHpOdVRMTXhGTjVFbmxtUG94STE5Vm1SNVUtbnlsUV9EcXVMZXlITzZvNzNSaUMyY3NqbHJacnBIOEdnQjIyRnVRUGZ4SWRGM2Uwc0JSWXFBckVac0YxakQ1dk9jLW8zVE9kRzJkb0lMQ3RFbko2TnVDLWwycjc5MW5C?oc=5","date":"2025-09-04","type":"earnings","source":"Yahoo Finance","summary":"Aspen Pharmacare Holdings Full Year 2025 Earnings: EPS Misses Expectations - Yahoo Finance","headline":"Aspen Pharmacare Holdings Full Year 2025 Earnings: EPS Misses Expectations","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE8zUXVXQU83aDRXYXVKLWFBN2FrUUw3NEFGQkVrYUdINlcwS2FxdllyaFlVYTExbmJ1SVZhWGV0U0NqNEl5TlZlVnBFMTdQSkpDY21Ccw?oc=5","date":"2023-09-27","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Bid Corporation Limited (BID.JO) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Bid Corporation Limited (BID.JO) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE96VTRXc1hTb05QMU9kMnVCTUlaQ0JUWWFjN1JKYUU4UUdMR2tPY2pxVnZ0QU1YbHRMSXBHVElYX0lzR0xuUHdkNUJ6TFc4MWhkTG9YNw?oc=5","date":"2020-06-09","type":"pipeline","source":"Yahoo Finance Singapore","summary":"KAL Group Limited (KAL.JO) stock price, news, quote and history - Yahoo Finance Singapore","headline":"KAL Group Limited (KAL.JO) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE82RDRudk1NRkVlYkdtNWxEOHljX2lWV0w2Vi0wMkZTRmhSY19lUXF1anJFUXZUY0hybjhidTdVQnlrRG9OU3ZPaUx3YklHYkpubkh5TA?oc=5","date":"2018-03-07","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Aspen Pharmacare Holdings Limited (APN.JO) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Aspen Pharmacare Holdings Limited (APN.JO) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Mebex","drugSlug":"pralidoxime","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":10800000},{"drugName":"Pentacarinat","drugSlug":"pentamidine","patentNumber":"","type":"Patent Cliff","expiryDate":"2026-06-01","territory":"US","annualRevenue":8100000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sandoz","Teva Pharmaceutical Industries","Mylan N.V."],"therapeuticFocus":["Oncology","Critical Care","Pain Management"],"financials":{"source":"yahoo_finance","revenue":2631856880.341,"revenuePeriod":"2025-06-30","revenueHistory":[{"period":"2025-06-30","value":2631856880.341},{"period":"2024-06-30","value":2713368394.542},{"period":"2023-06-30","value":2470776047.363},{"period":"2022-06-30","value":2343137391.842}],"grossProfit":1161008008.303,"grossProfitHistory":[{"period":"2025-06-30","value":1161008008.303},{"period":"2024-06-30","value":1180733430.5779998},{"period":"2023-06-30","value":1117247917.656},{"period":"2022-06-30","value":1111057169.7419999}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":331265707.006,"operatingIncome":523482360.375,"operatingIncomeHistory":[{"period":"2025-06-30","value":523482360.375},{"period":"2024-06-30","value":634005418.722},{"period":"2023-06-30","value":500540176.92899996},{"period":"2022-06-30","value":533557499.13699996}],"netIncome":-65731176.381,"netIncomeHistory":[{"period":"2025-06-30","value":-65731176.381},{"period":"2024-06-30","value":267294645.228},{"period":"2023-06-30","value":317306177.39599997},{"period":"2022-06-30","value":393780122.21599996}],"eps":-2.439,"epsHistory":[{"period":"2025-06-30","value":-2.439},{"period":"2024-06-30","value":9.914},{"period":"2023-06-30","value":11.769},{"period":"2022-06-30","value":14.323}],"cash":388985327.26299995,"cashHistory":[{"period":"2025-06-30","value":388985327.26299995},{"period":"2024-06-30","value":748777029.559},{"period":"2023-06-30","value":662288639.584},{"period":"2022-06-30","value":375268572.081}],"totalAssets":8247836336.051,"totalLiabilities":3095373957,"totalDebt":2192253084.8399997,"equity":5152462379.051,"operatingCashflow":313118318.513,"operatingCashflowHistory":[{"period":"2025-06-30","value":313118318.513},{"period":"2024-06-30","value":377817703.575},{"period":"2023-06-30","value":335028710.64},{"period":"2022-06-30","value":326167444.018}],"capex":-306806183.385,"capexHistory":[{"period":"2025-06-30","value":-306806183.385},{"period":"2024-06-30","value":-335939114.745},{"period":"2023-06-30","value":-193066363.86699998},{"period":"2022-06-30","value":-163690658.079}],"freeCashflow":6312135.128,"dividendsPaid":-97170464.807,"buybacks":-4127165.2759999996,"employees":9128,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14092,"previousClose":14196,"fiftyTwoWeekHigh":15151,"fiftyTwoWeekLow":9070,"fiftyTwoWeekRange":"9070.0 - 15151.0","fiftyDayAverage":13611.16,"twoHundredDayAverage":11310.25,"beta":0.34,"enterpriseValue":5489033826.013364,"forwardPE":11.5,"priceToBook":0.77,"priceToSales":1.47,"enterpriseToRevenue":2.12,"enterpriseToEbitda":11.89,"pegRatio":0,"ebitda":461756962.056,"ebitdaMargin":17.9,"freeCashflow":-1072820150.7193098,"operatingCashflow":420667378.46382743,"totalDebt":1999429468.210264,"debtToEquity":40.6,"currentRatio":3.63,"returnOnAssets":2.9,"returnOnEquity":-2.2,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":15050,"targetHighPrice":17500,"targetLowPrice":13600,"dividendRate":2.11,"payoutRatio":0.36,"fiveYearAvgDividendYield":1.25,"exDividendDate":1759276800,"insiderHeldPercent":7.7,"institutionHeldPercent":63.7,"sharesOutstanding":444022553,"floatShares":366577146,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-4.07,"epsForward":12.24,"revenuePerShare":95.87,"bookValue":182.38,"officers":[{"age":61,"name":"Mr. Stephen Bradley Saad BCom, CA(SA)","title":"Group CEO & Executive Director"},{"age":58,"name":"Mr. Sean M. Capazorio","title":"Group CFO & Executive Director"},{"age":61,"name":"Ms. Lorraine  Hill","title":"Group Chief Operations Officer"},{"age":64,"name":"Mr. Michael Guy Attridge B.Com., CA(SA)","title":"Group Chief Advisor"},{"age":null,"name":"Ms. Sibongakonke  Nkosi","title":"Investor Relations Manager"},{"age":53,"name":"Mr. Trevor Julian Ziman","title":"Regional Chief Executive Officer of Asia Pacific"},{"age":34,"name":"Ms. Raeesa  Khan","title":"Group Company Secretary & Chief of Staff"},{"age":50,"name":"Mr. Samer  Kassem","title":"Chief Executive Officer of Aspen Global Incorporated"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.aspenpharma.com/default.aspx?pid=5&stepid=1&oid=5","website":"https://www.aspenpharma.com","phone":"27 31 580 8600"}}